Found: 6
Select item for more details and to access through your institution.
Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 305, doi. 10.1016/j.clml.2021.10.012
- By:
- Publication type:
- Article
Effect of ruxolitinib cream on achievement of VASI50 by body region: Week 52 pooled analysis of the TRuE-V phase 3 studies.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. i4, doi. 10.1093/bjd/ljac106.005
- By:
- Publication type:
- Article
Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Week 52 pooled subgroup analysis from two randomized phase 3 studies.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. i5, doi. 10.1093/bjd/ljac106.006
- By:
- Publication type:
- Article
624 - Vitiligo biomarker CXCL10 correlates with clinical response in the phase 2 randomized, double-blind, vehicle-controlled TRuE-V mechanism of action study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.008
- By:
- Publication type:
- Article
Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii66, doi. 10.1093/bjd/ljad498.067
- By:
- Publication type:
- Article
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0417-z
- By:
- Publication type:
- Article